Luisa Ibáñez

Luisa Ibáñez

Auto-generated profile, based on publicly available information

Luisa Ibáñez

Fundació Institut Català de Farmacologia, Barcelona

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Gastroenterology
Verified
Journal Article
Open access
PDF file
Mª Isabel LucenaMª Isabel Lucena
Mª Isabel Lucena
MMMariam Molokhia
Mariam Molokhia
YSYufeng Shen
Yufeng Shen
TUThomas J. Urban
Thomas J. Urban
GAGuruprasad Aithal
Guruprasad Aithal
ADAnn Daly
Ann Daly
Background & Aims Drug-induced liver injury (DILI), especially from antimicrobial agents, is an important cause of serious liver disease. Amoxicillin-clavulanate (AC) is a leading cause of idiosyncratic DILI, but little is understood about genetic susceptibility to this adverse reaction. Methods We performed a genome-wide association study using 822,927 single nucleotide polymorphism (SNP) markers from 201 White European and US cases of DILI following AC administration (AC-DILI) and 532 population controls, matched for genetic background. Results AC-DILI was associated with many loci in the major histocompatibility complex. The strongest effect was with an HLA class II SNP (rs9274407, P = 4.8 × 10−14), which correlated with rs3135388, a tag SNP of HLA-DRB1*1501-DQB1*0602 that was previously associated with AC-DILI. Conditioned on rs3135388, rs9274407 is still significant (P = 1.1 × 10−4). An independent association was observed in the class I region (rs2523822, P = 1.8 × 10−10), related to HLA-A*0201. The most significant class I and II SNPs showed statistical interaction (P = .0015). High-resolution HLA genotyping (177 cases and 219 controls) confirmed associations of HLA-A*0201 (P = 2 × 10−6) and HLA-DQB1*0602 (P = 5 × 10−10) and their interaction (P = .005). Additional, population-dependent effects were observed in HLA alleles with nominal significance. In an analysis of autoimmune-related genes, rs2476601 in the gene PTPN22 was associated (P = 1.3 × 10−4). Conclusions Class I and II HLA genotypes affect susceptibility to AC-DILI, indicating the importance of the adaptive immune response in pathogenesis. The HLA genotypes identified will be useful in studies of the pathogenesis of AC-DILI but have limited utility as predictive or diagnostic biomarkers because of the low positive predictive values.

1 April 2017 in Gastroenterology
Verified
Journal Article
Open access
PDF file
PNPaola Nicoletti
Paola Nicoletti
GAGuruprasad Aithal
Guruprasad Aithal
EBEinar S. Bjornsson
Einar S. Bjornsson
RARaul J. Andrade
Raul J. Andrade
ASAshley Sawle
Ashley Sawle
ADAnn Daly
Ann Daly
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. Methods We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls. The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America. For the GWAS, we included only cases with patients of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. After the discovery analysis was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI associated with various drugs. Results We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9−3.8; P = 2.4 × 10−8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6−2.5; P = 9.7 × 10−9). The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the association between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was associated with cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6−2.7; P = 4.8 × 10−9). We did not associate any specific drug classes with genetic polymorphisms, except for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0−9.5; P = 7.1 × 10−9). We validated the association between A*33:01 terbinafine- and sertraline-induced DILI. We could not validate the association between DILI and rs72631567, rs28521457, or rs116561224. Conclusions In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified polymorphisms that appear to be associated with DILI from statins, as well as 2 non−drug-specific risk factors.

1 January 2004 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JLJoan-Ramon Laporte
Joan-Ramon Laporte
LILuisa Ibanez
Luisa Ibanez
XVXavier Vidal
Xavier Vidal
LVLourdes Vendrell
Lourdes Vendrell
RLRoberto Leone
Roberto Leone

25 April 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
LILuisa Ibáñez
Luisa Ibáñez
XVXavier Vidal
Xavier Vidal
EBElena Ballarín
Elena Ballarín
JLJoan-Ramon Laporte
Joan-Ramon Laporte
Research from JAMA Internal Medicine — Population-Based Drug-Induced Agranulocytosis

1 April 2008 in Haematologica
Verified
Journal Article
Open access
PDF file
EMEva Montané
Eva Montané
LILuisa Ibáñez
Luisa Ibáñez
XVXavier Vidal
Xavier Vidal
EBElena Ballarín
Elena Ballarín
RPRamon Puig
Ramon Puig
TAthe Catalan Group for the Study of Agranulocytosis and Aplastic Anemia
the Catalan Group for the Study of Agranulocytosis and Aplastic Anemia
Background Aplastic anemia is a rare and severe disease. Its incidence varies considerably worldwide. We aimed at describing the epidemiology of this disease, including the incidence, mortality and survival trends, in a well-defined population. Design and Methods Since 1980, a case-control surveillance study of aplastic anemia has been carried out by a cooperative group, in the metropolitan area of Barcelona. Inclusion is dependent on the patient having at least two of the following features: white blood cell count ≤3.5×109/L, platelet count ≤50×109/L, hemoglobin <10 g/L or hematocrit of <30%; when only one of these last two criteria is fulfilled, a reticulocyte count of ≤30×109/L is also required. The bone marrow biopsy has to be compatible with the diagnosis of aplastic anemia. Results Between 1980 and 2003, a total of 235 cases of aplastic anemia were identified. The overall incidence was 2.34 per million inhabitants per year and the incidence increased with age. Most of the cases were classified as severe or very severe aplastic anemia. Survival rates at 3 months, and at 2 and 15 years after the diagnosis were 73%, 57%, and 51%, respectively. Advanced age and more severe disese at the time of diagnosis were associated with a lower survival rate. There was a trend to a better 2-year survival rate among patients treated with bone marrow transplantation. Forty-nine cases (20.8%) were exposed to drugs reported to be associated with aplastic anemia, and 21 (8.9%) to toxic agents. Conclusions The incidence of aplastic anemia in Barcelona is low but the case fatality rate is high. Advanced age and severe disease at the time of diagnosis were associated with decreased survival.

3 December 2004 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
XVXavier Vidal
Xavier Vidal
JLJoan-Ramon Laporte
Joan-Ramon Laporte
LILuisa Ibáñez
Luisa Ibáñez
EBElena Ballarín
Elena Ballarín